Brief: Cantargia Reports New Preclinical Data Confirming Potential Of Nadunolimab, Can10

Cantargia AB

24/11/2023 14:45

Nov 24 (Reuters) - Cantargia AB  CANTA.ST :
    * REPORTS NEW PRECLINICAL DATA CONFIRMING THE POTENTIAL OF NADUNOLIMAB AND CAN10
    * DATA SHOWS THAT IL1RAP BLOCKADE RESULTS IN REDUCED VASCULAR INFLAMMATION
    * DATA SHOWS THAT LEVELS OF IL1RAP CORRELATE WITH VARIOUS INFLAMMATORY MARKERS IN INFLAMED
TISSUE.

Source text for Eikon:  ID:nMFN3SFxhq 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))